A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

GLP-1 medications can help people lose weight, but food retailers can help them keep it off and stay healthy Dietitians can ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The convenience store segment faced economic challenges in 2024 with shifting consumer preferences, consolidation, inflation ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

"Don’t treat the doctor's office like an assignment. Think of it like BODY MAINTENANCE. You’d do it for your car, right?" ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...